Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of ...
""Given the encouraging clinical activity observed for cabozantinib in phase 1 and 2 trials in differentiated thyroid cancer, and the poor prognosis for ..."
Published: Feb 24th, 2020 2:56 PM
Repurposing Astellas' and Novartis' leukemia drugs in resistant lung cancer
"Blueprint Medicines is studying a combination of Tagrisso with its RET inhibitor BLU-667 in patients with advanced EGFR-mutant NSCLC who also ..."
Published: Feb 24th, 2020 1:03 PM
Predictive Markers for mCRC
"We know there is the BLU-667 compound and there's a LOXO-292 compound that's currently out there being used for thyroid and lung cancer. And the ..."
Published: Feb 21st, 2020 11:45 PM
Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce ...
"Trulicity may cause tumors in the thyroid, including thyroid cancer. ... have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC)."
Published: Feb 20th, 2020 1:07 PM
Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief ...
"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."
Published: Feb 19th, 2020 11:00 AM
Tmunity to Present at Upcoming Investor Conferences
"PHILADELPHIA--(BUSINESS WIRE)-- Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving ..."
Published: Feb 14th, 2020 3:25 PM
Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark
"Blueprint Medicines initiated the rolling submission of NDA to the FDA for its precision therapy pralsetinib to address the RET fusion-positive ..."
Published: Feb 13th, 2020 7:03 PM
Blueprint Medicines Corporation's (BPMC) CEO Jeff Albers on Q4 2019 Results - Earnings Call ...
"This morning in addition to financial results for 2019, we will highlight key value drivers for Blueprint Medicines in 2020, discuss topline pralsetinib in ..."
Published: Feb 13th, 2020 1:15 PM
EU Speedy Review Success For Kite But Not For Lilly
"... therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib ..."
Published: Feb 13th, 2020 11:00 AM
Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
"Announced top-line ARROW trial data for pralsetinib in RET fusion-positive NSCLC and initiated rolling NDA -. - Plan to present initial PIONEER trial ..."
Published: Feb 12th, 2020 3:41 PM
FDA Speeds Up Examination of 5 Drugs with Priority Review
"... RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. With priority review, Eli Lilly is anticipating potential approval ..."
Published: Feb 12th, 2020 2:56 PM
Stock To Watch: Blueprint Medicines (BPMC)
"A New Drug Application for Pralsetinib for previously treated RET-mutant medullary thyroid cancer is expected to be filed with the FDA in the second ..."
Published: Feb 11th, 2020 10:48 AM
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
"... the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier."
Published: Feb 11th, 2020 10:03 AM
Exelixis bounces back with new prostate cancer data
"Exelixis bounces back with new prostate cancer data ... as a treatment for progressive, metastatic medullary thyroid cancer in the US and Europe."
Published: Feb 10th, 2020 7:48 PM
Testing for RET Fusions in NSCLC Remains Critical as Targeted Therapy BLU-667 Evolves
"The selective RET inhibitor BLU-667 has demonstrated durable responses in patients with RET fusion-positive lung cancer in the phase I ARROW ..."
Published: Feb 8th, 2020 1:03 PM
A Look Back at FDA News from January 2020
"... Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer ... non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET ..."
Published: Feb 4th, 2020 7:48 PM
Jennifer Jeske, 47
"The family appreciates memorials to ThyCa Donation, Attn: Medullary Thyroid Cancer Research Fund, P.O. Box 1102, Olney, Maryland, 20830-1102."
Published: Feb 4th, 2020 2:00 PM
Investigators Seek New Standard in RET Fusion-Positive NSCLC
"Investigators hope selpercatinib (LOXO-292), a highly selective RET inhibitor, will demonstrate potential as a new standard of care (SOC) for patients ..."
Published: Feb 4th, 2020 1:48 PM
Takeda unveils profit surprise on Shire integration-and no US Natpara supply till 2021
"Takeda doesn't expect any Natpara sales in the U.S. into fiscal 2020 ending in March 2021, as discussions with FDA to resume supply after a recent ..."
Published: Jan 31st, 2020 5:00 PM
FDA Grants Priority Review to Selpercatinib for Lung and Thyroid Cancer Subsets
"The application is based on findings from the phase I/II LIBRETTO-001 trial, which evaluated selpercatinib in RET-altered NSCLC and thyroid cancers."
Published: Jan 30th, 2020 3:50 PM
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
"... non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer ... Many industry players are adopting this method to bring new cancer ..."
Published: Jan 30th, 2020 3:41 PM
Lilly's NDA for Selpercatinib Gets FDA's Priority Review
"The company plans to complete the NDA submission for pralsetinib in the first quarter of 2020 to treat NSCLC while the same for the MTC indication is ..."
Published: Jan 30th, 2020 11:33 AM
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
"... review for selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and thyroid cancer ..."
Published: Jan 30th, 2020 6:18 AM
Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers
"Lilly's selpercatinib gets FDA priority review for lung and thyroid cancers ... fusion-positive thyroid cancer, and RET-mutant medullary thyroid cancer ..."
Published: Jan 30th, 2020 1:54 AM
CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST
"... RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer has been granted priority review by the FDA - with a decision expected ..."
Published: Jan 29th, 2020 4:37 PM
FDA grants priority review to selpercatinib for RET-altered NSCLC, thyroid cancer
"The FDA granted priority review to selpercatinib for the treatment of advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary ..."
Published: Jan 29th, 2020 4:03 PM
FDA Grants Priority Review to Selpercatinib in RET Fusion+ NSCLC and Thyroid Cancer
"The New Drug Application (NDA) for selpercatinib (LOXO-292) was granted FDA Priority Review for the treatment of patients with advanced RET ..."
Published: Jan 29th, 2020 12:24 PM
Bay Street Likely To Open Higher
"Eli Lilly has applied for approval of the treatment in three different types of tumors with altered RET: non-small-cell lung cancer, medullary thyroid ..."
Published: Jan 29th, 2020 12:18 PM
Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning Sign
"Thyroid Cancer Symptom: A Lump On This Body Part Could Be An Early Warning ... At its initial stages, thyroid cancer might not exhibit any symptoms. ... syndromes including Cowden's syndrome, familial medullary thyroid cancer, ..."
Published: Jan 29th, 2020 10:48 AM
Lilly's selpercatinib application nabs accelerated review in US
"... advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer."
Published: Jan 29th, 2020 10:37 AM
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
"... RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer."
Published: Jan 27th, 2020 7:15 PM
National Brain Tumor Society Backs Oncoceutics' Phase II Trial for Subset of High-Grade Gliomas
"ONC201 is the first imipridone dopamine receptor D2 antagonist (DRD2) that treats high-grade glioma by selectively targeting G protein-coupled ..."
Published: Jan 24th, 2020 5:33 PM
Patients with Hypoparathyroidism Warned of Extended NATPARA Recall
"NATPARA was voluntarily pulled off the market by the manufacturer (Takeda) after small particles of rubber were found in some samples of the ..."
Published: Jan 24th, 2020 3:52 AM
Trial drug ONC201 hopes for wife of Boro coach Graeme Lee
"FOOTBALL fans in the North-East are being urged to show their support for the wife of a former player. Graeme Lee started his career with Hartlepool ..."
Published: Jan 23rd, 2020 11:00 PM
CStone successfully hosted the first US R&D Day in New York
"A total of five NDA submissions in Mainland China and Taiwan for CS1001, an anti-PD-L1 monoclonal antibody; pralsetinib, a RET inhibitor; and ..."
Published: Jan 23rd, 2020 1:02 PM
Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors
"The company's pipeline of drug candidates also includes TPX-0022, ... or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, ..."
"... global commercial infrastructure to support additional planned regulatory filings and commercial launches for AYVAKIT and pralsetinib, if approved, ..."
Published: Jan 21st, 2020 8:00 PM
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
"... to fund clinical trials for pralsetinib in RET-driven cancers, including its Phase 3 AcceleRET Lung clinical trial for pralsetinib in first-line RET-altered ..."
Published: Jan 20th, 2020 5:00 PM
Pralsetinib effective, safe for RET fusion-positive NSCLC
"Approximately 90% of patients with advanced medullary thyroid cancer have RET mutations. The ongoing phase 1/phase 2 ARROW trial evaluated ..."
Published: Jan 20th, 2020 10:03 AM
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
"Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in a phase 1/2 trial for non-small cell ..."
Published: Jan 17th, 2020 11:33 AM
Tmunity doses first patient in Phase 1 CART-TnMUC1 clinical trial
"Tmunity Therapeutics Inc., a clinical-stage biotherapeutics firm focused on advanced T-cell immunotherapy, has reportedly dosed the first patient in its ..."
Published: Jan 16th, 2020 10:15 PM
FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...
"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.Do not use ..."
Published: Jan 16th, 2020 9:52 PM
FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and ...
"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use ..."
Published: Jan 16th, 2020 6:07 PM
A venture firm warms to funding neuroscience
"But only three - the cell therapy companies Kyverna, Tmunity, and Arsenal Biosciences - are publicly known. Any hints? Unlock this article by ..."
Published: Jan 15th, 2020 11:00 AM
Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
"Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of ..."
Published: Jan 13th, 2020 12:52 PM
Turning Point Therapeutics Announces Program Updates and Milestones for 2020
"Multiple RET-Positive Patients with Solvent-Front Mutations Previously Treated with Other Investigational RET Inhibitors Dosed with TPX-0046"
"Multiple marketing applications for avapritinib and pralsetinib currently under review or planned for submission in 2020, including 5 in the U.S. and 2 ..."
Published: Jan 11th, 2020 8:00 PM
Thyroid cancer is somewhat mysterious
"Thyroid cancer is one of the rarer cancers and not in the list of the top 10 ... The medullary thyroid cancer (MTC) comes from a different cell in the ..."
Published: Jan 10th, 2020 10:26 PM
GIST kissed ahead of V-Day PDUFA, Blueprint design plan for Ayvakit goes 'fourth'
"Blueprint also plans to submit, in the second quarter, an NDA to the FDA for pralsetinib for medullary thyroid cancer previously treated with an ..."
Published: Jan 10th, 2020 6:52 PM
Pralsetinib Achieves Durable Responses in Patients With RET+ NSCLC
"Pralsetinib (BLU-667), a highly-selected RET inhibitor, achieved a favorable overall response rate (ORR) with prolonged durability in patients with ..."
Published: Jan 10th, 2020 4:05 PM
Top-Line Data Reported for Pralsetinib in Patients with RET Fusion-Positive NSCLC
"... to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously treated with an approved multikinase inhibitor."
Published: Jan 9th, 2020 8:56 PM
Turning Point Therapeutics Announces Management Transition
"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."
Published: Jan 9th, 2020 1:37 PM
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
"Notably, pralsetinib is also being studied for RET-mutant medullary thyroid carcinoma (MTC). The company plans to complete the NDA submission for ..."
Published: Jan 9th, 2020 1:36 PM
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
"The ARROW study evaluated once-daily oral, pralsetinib in 80 patients with RET fusion-positive NSCLC who received prior treatment with ..."
Published: Jan 9th, 2020 10:15 AM
Thyroid Cancer Drug Market Had A Booming Decade || Celgene Corporation, AstraZeneca ...
"Global thyroid cancer drug market is rise gradually to an estimated value of ... thyroid cancer, Follicular thyroid cancer, Hurthle cell cancer, Medullary ..."
Published: Jan 9th, 2020 8:22 AM
Turning Point (TPTX) Marches Ahead, Awaits TRIDENT-1 Data Update In 2020
"Next up in the pipeline TPX-0046 is under phase I/II study for the treatment of advanced solid tumors with abnormal RET genes. Another clinical drug ..."
Published: Jan 8th, 2020 10:15 PM
Blueprint Reports High Response Rates From Lung Cancer Patients in Early Pralsetinib Trials
"In the second quarter, the company plans to file an NDA for the medullary thyroid cancer indication. RET fusions appear in approximately 1 to 2 ..."
Published: Jan 8th, 2020 4:15 PM
Lilly looms over Blueprint as the biotech files targeted cancer drug
"The biotech also intends to ask regulators to approve pralsetinib as a treatment for medullary thyroid cancer, with an application planned for the ..."
Published: Jan 8th, 2020 2:36 PM
Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission
"Its most advanced competitor is Indianapolis-based Eli Lilly's Loxo Oncology division, whose RET inhibitor LOXO-292 (selpercatinib) has also shown ..."
Published: Jan 8th, 2020 2:33 PM
Blueprint throws down targeted therapy gauntlet with new lung cancer data, FDA submission
"... Medicines said Wednesday that it had started a rolling submission to the Food and Drug Administration for the drug BLU-667 (pralsetinib), based on ..."
Published: Jan 8th, 2020 11:56 AM
Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission ...
"Blueprint Medicines also plans to submit an NDA to the FDA for pralsetinib for the treatment of patients with medullary thyroid cancer (MTC) previously ..."
Published: Jan 7th, 2020 6:37 PM
Orphan Drugs Market Growth Strategies by 2027 with Leading Key Players Takeda ...
"Based on disease the market is segmented into Hodgkin lymphoma, ... 1 (GD1), Metastatic medullary thyroid carcinoma, Advanced gastric cancer or ..."
Published: Jan 7th, 2020 1:03 PM
Thyroid nodules: diagnostic evaluation based on thyroid cancer risk assessment
"We focus on the concept of risk assessment for thyroid cancer at different stages of the diagnostic pathway for ...... MTC-medullary thyroid cancer."
Published: Jan 4th, 2020 11:00 AM
Plea for access to new drug for girl diagnosed with brain cancer
"The new drug, ONC201, is being trialled in the USA and Germany but not ... ONC201 has been shown to kill tumour cells in studies overseas but the ..."
Published: Jan 2nd, 2020 2:00 PM
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
"She joins from Tmunity Therapeutics, where she also served as chief medical ... At Tmunity, she was responsible for the development of the company's ..."
Published: Jan 1st, 2020 2:00 PM
Video Series Offers Support to Cancer Caregivers
"The American Cancer Society (ACS) created a video series for caregiver support to address their most-asked ... RET-Mutant Medullary Thyroid Cancer"
Published: Dec 31st, 2019 5:56 PM
CURE's Clinical Trial Corner: December 2019
"The trial will enroll 400 patients with advanced or metastatic RET-mutant medullary thyroid cancer who have received no prior systemic therapy for ..."
Published: Dec 30th, 2019 8:00 PM
Lilly opens Phase III trial of highly targeted Loxo drug in thyroid cancer
""This Phase III trial of selpercatinib in patients advanced or metastatic ... The thyroid cancer trial is randomizing patients to receive selpercatinib or ..."
Published: Dec 30th, 2019 3:41 PM
Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer
"Selpercatinib is an orally administered drug in clinical development for cancers with abnormalities in the rearranged during transfection (RET) kinase."
Published: Dec 30th, 2019 11:56 AM
Lilly launches late-stage study of LOXO-292 in medullary thyroid cancer
"Eli Lilly (NYSE:LLY) initiates a Phase 3 clinical trial, LIBRETTO-531, evaluating selpercatinib (LOXO-292) in previously untreated patients with ..."
Published: Dec 30th, 2019 10:37 AM
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
"Randomized trial will examine selpercatinib against standard of care in 400 patients with advanced or metastatic treatment-naieve RET-mutant..."
Published: Dec 27th, 2019 5:56 PM
First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC
"Breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and RETfusion-positive thyroid cancers have ..."
Published: Dec 25th, 2019 12:19 PM
Thyroid Cancer Treatment Market Will Generate New Growth Opportunities in the Next Upcoming ...
"Follicular cancer, medullary cancer, and Anaplastic cancer are different types of thyroid cancers. The treatments which is available for thyroid cancer ..."
Published: Dec 23rd, 2019 12:30 PM
New medical chief at Rubius Therapeutics
"Dr. Coughlin joins Rubius from Tmunity Therapeutics, where she served as CMO and was responsible for the development of Tmunity's CAR-T and ..."
Published: Dec 23rd, 2019 12:02 PM
Rubius Therapeutics Appoints Christina Coughlin, MD, Ph.D., as Chief Medical Officer
"A trained oncologist and immunologist, Dr. Coughlin joins Rubius from Tmunity Therapeutics, Inc., where she served as chief medical officer and was ..."
Published: Dec 18th, 2019 2:56 PM
Natpar(a): A Case in Point for Rare Disease Drugs?
"While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the ..."
Published: Dec 17th, 2019 8:56 PM
Eli Lilly Shines With BTK Inhibitor Drug In Treating B-Cell Leukemias And Lymphomas
"It used its drug LOXO-305 to treat B-Cell Leukemias and Lymphomas. ... Eli Lilly's other product from the acquisition of LOXO, known as LOXO-292, ..."
Published: Dec 17th, 2019 4:15 PM
RET Inhibitor Trial Updates at ASCO and ESMO
"... the BLU-667 agent in medullary thyroid cancer predominantly. That, again, showed extremely good response rate, with a total response rate, overall ..."
Published: Dec 17th, 2019 4:03 PM
ESMO 2019 LIBRETTO-001 Trial Updates
"... an update of the LIBRETTO-001 study for differentiated thyroid cancer and medullary thyroid cancer was presented, and the partial response was in ..."
Published: Dec 17th, 2019 3:52 PM
LOXO-292 in Patients With RET-Fusion Lung Cancer
"LOXO-292 in Patients With RET-Fusion Lung Cancer. Insights From: Jacob Sands, MD, Dana-Farber Cancer Institute; Benjamin Besse, MD, PhD, ..."
Published: Dec 17th, 2019 1:05 PM
Turning Point Therapeutics to Participate in 38th Annual JP Morgan Healthcare Conference
"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."
Published: Dec 16th, 2019 4:03 PM
Top M&A Deals in 2019
"LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial ..."
Published: Dec 13th, 2019 2:14 PM
Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why
"Pralsetinib (formerly BLU-667) in being studied in the phase I/II ARROW study evaluating previously-treated patients with receptor tyrosine RET-fusion ..."
Published: Dec 13th, 2019 1:37 PM
Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why
"... is being evaluated in several late-stage studies for cancer indications. ... lung cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC)."
Published: Dec 13th, 2019 11:00 AM
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
"Lilly Initiates Lung Cancer Study on Selpercatinib: Lilly began a phase III study to evaluate its oral RET inhibitor, selpercatinib/LOXO-292in previously ..."
Published: Dec 12th, 2019 2:33 PM
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."
Published: Dec 12th, 2019 1:03 PM
Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
"Eli Lilly and Company LLY initiated a phase III LIBRETTO-431 study (NCT04194944) on its oral RET inhibitor, selpercatinib (LOXO-292), ..."
Published: Dec 12th, 2019 8:33 AM
Lilly launches first of its kind trial for RET fusion-positive NSCLC
"The LIBRETTO-431 clinical trial is assessing selpercatinib, also known as LOXO-292, for treatment-naiive RET fusion-positive non-small cell lung ..."
Published: Dec 11th, 2019 8:11 PM
Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug
"The trial will examine the effects of selpercatinib (LOXO-292) in cancer patients who have had no prior treatment for their condition. Participants will be ..."
Published: Dec 11th, 2019 4:48 PM
Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...
"Selpercatinib has received breakthrough designations in RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC) and RET ..."
Published: Dec 11th, 2019 10:48 AM
Lilly opens late-stage RET fusion-positive NSCLC study
"Eli Lilly (NYSE:LLY) launches the Phase 3 LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naiive RET ..."
Published: Dec 11th, 2019 10:37 AM
Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naiive RET Fusion-Positive ...
"Enrolled trial participants will be randomized to receive either selpercatinib or platinum-based (carboplatin or cisplatin) and pemetrexed therapy with ..."
Published: Dec 11th, 2019 1:39 AM
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based ...
"A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without ..."
Published: Dec 10th, 2019 5:41 AM
HR and Talent Acquisition Manager
"Tmunity Therapeutics is seeking a strong talent acquisition and human resources manager to manage..."
Published: Dec 9th, 2019 2:00 PM
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
"... Test to identify certain non-small cell lung cancer and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."
Published: Dec 9th, 2019 9:40 AM
Executive of the Year: Josh Bilenker, Loxo Oncology
"Another, known as selpercatinib, drew Eli Lilly to negotiate what became an $8 billion buyout of Loxo in the opening days of 2019. Measured from the ..."
Published: Dec 3rd, 2019 7:03 PM
Woman with 100 cancerous tumours in her lungs refuses to find out prognosis
"A woman who was diagnosed with cancer when she was just 21 was ... result, but an ultrasound revealed Ashley had medullary thyroid cancer."
Published: Dec 2nd, 2019 4:03 PM
Potential Gene Mutation May Help to Identify Familial Thyroid Cancer
""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for 6%-10% of cases," lead study author Darrin ..."
Published: Dec 2nd, 2019 2:33 PM
Drug Recall in US Causes Hypoparathyroid Patients Extreme Hardship
"The recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States over safety concerns about the product is ..."
Published: Nov 27th, 2019 10:25 PM
Wichita nonprofit trying to save clinical trial helping young brain cancer patients
"But that grim outlook is different with the drug ONC201. Ward is among the patients participating in a clinical trial for the drug. He says, statistically, he ..."
Published: Nov 27th, 2019 1:26 PM
Treatments Improve PFS in Thyroid Cancer
"Treatments Improve PFS in Thyroid Cancer ... are another 2 drugs that can delay the progression of disease in patients with medullary thyroid cancer."
Published: Nov 26th, 2019 7:03 PM
Molecular Testing Moves in Front of Systemic Treatment for Certain Thyroid Cancers
"Upfront biomarker testing is now recommended for patients with differentiated thyroid cancer (DTC) or medullary thyroid cancer (MTC) since targeted ..."
Published: Nov 22nd, 2019 4:48 PM
Kansas family hoping for miracle for 5-year-old with inoperable cancer
""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey said."
Published: Nov 21st, 2019 10:13 PM
Olathe family hoping for miracle for 5-year-old with inoperable cancer
""We're narrowing in on this ONC201 trial that is out there because it's the only thing that we can see that may give us a shred of hope," Stacey Sands ..."
Published: Nov 20th, 2019 7:48 PM
LIBRETTO-001 Regimen Overview
"In contrast, selpercatinib is a selective RET inhibitor that very meaningfully hits RET but avoids these other targets that can result in adverse effects in ..."
Published: Nov 20th, 2019 7:37 PM
RET Testing in Papillary and Medullary Thyroid Cancer
"The same is true in medullary thyroid cancer, where both vandetanib and cabozantinib work in patients both with and without RET mutations."
Published: Nov 20th, 2019 7:26 PM
RET Treatment: Novel Compounds to Replace Current TKIs
"Marcia Brose, MD, PhD: In medullary thyroid cancer we have these 2 agents. As I just mentioned in the toxicity discussion, these clearly are not agents ..."
Published: Nov 20th, 2019 3:52 PM
Phase 2 Trial of TransCon PTH to Speed Enrollment of Patients Affected by US Recall of Natpara
"A Phase 2 trial testing the experimental therapy TransCon PTH in adults with hypoparathyroidism is expanding to allow for faster enrollment of people ..."
Published: Nov 20th, 2019 1:03 PM
Researchers identify new gene mutation in familial thyroid cancers
""Thyroid cancer is common and on the rise, and hereditary non-medullary thyroid cancers account for six to ten percent of cases," said Bann. "Prior to ..."
Published: Nov 19th, 2019 8:45 PM
RET Fusion, Point Mutation, and Signaling
"It is often found in papillary thyroid cancer in that form. That's the contrast with medullary thyroid cancer, where you'll actually have point mutations."
Published: Nov 19th, 2019 6:41 PM
'Stay tuned:' Neoadjuvant therapy in thyroid cancer still needs research
"... with medullary thyroid cancer who have RET mutations and in those with RET-fusion papillary, poorly differentiated and anaplastic thyroid cancer."
Published: Nov 19th, 2019 1:03 PM
Investigational Drug Shows Promise in Patients with RET-Altered Cancers
"Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from ..."
Published: Nov 18th, 2019 1:03 PM
How gene-edited white blood cells are helping fight cancer
"... scientists from the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco and Tmunity Therapeutics, a biotech ..."
"Previously, patients treated with NATPARA were required to undergo a long washout period prior to entering screening in PaTH Forward. In response ..."
Published: Nov 12th, 2019 12:33 PM
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
"The company's pipeline of drug candidates also includes TPX-0022, ... and TPX-0046, targeting RET and SRC, which is currently being studied in a ..."
Published: Nov 12th, 2019 12:08 PM
New Online Reality Series with Actor, Comedian Billy Gardell Chronicles Type 2 Diabetes ...
"It is not known if Ozempic will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use ..."
Published: Nov 11th, 2019 9:39 PM
Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC
"Encouragingly, selpercatinib (formerly LOXO-292) and BLU-667 have shown greater tolerability. Although selpercatinib has shown a slightly higher ..."
Published: Nov 11th, 2019 2:04 PM
Orphan Drug Recall Leaves Patients in the Lurch
"And since Takeda's Natpara (parathyroid hormone) injection is the only effective treatment for Shelton, she knew when she received an official Takeda ..."
Published: Nov 11th, 2019 12:30 PM
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC ...
"TPX-0046 is a compact tyrosine kinase inhibitor (TKI) designed to target tumors with RET alterations and potentially overcome resistance that may ..."
Published: Nov 10th, 2019 4:02 AM
Current Concepts in Head and Neck Surgery
"Incorporate a multidisciplinary approach in the management of tumors of ... well differentiated/de-differentiated/anaplastic/medullary thyroid cancers, ..."
Published: Nov 9th, 2019 11:08 PM
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
"ONC201 is a dopamine receptor D2 (DRD2) antagonist that penetrates the blood brain barrier. ONC201 efficacy has been shown in glioblastoma ..."
Published: Nov 9th, 2019 2:32 AM
Thyroid cancer at a glance
"There are four types of thyroid cancer: papillary, follicular, medullary and anaplastic. How serious the illness is and the kind of treatment you get ..."
Published: Nov 8th, 2019 3:17 PM
Next-Generation Sequencing Sets Sights On Rare Mutations in Lung Cancer
"With selpercatinib, as well as BLU-667, there is hope for a better targetable option here. Both medications are well tolerated. Selpercatinib had a bit of ..."
Published: Nov 7th, 2019 9:16 AM
Early Results from First-In-US Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest ...
"Penn is conducting the ongoing study in cooperation with the Parker Institute for Cancer Immunotherapy (PICI) and Tmunity Therapeutics. "This trial is ..."
Published: Nov 7th, 2019 7:30 AM
Tmunity Raises $75 Million in Series B funding for T-cell Therapies Advancement
"In a new development that must have come as a big boost to the company and the wider industry, Tmunity has managed to raise as much as $75 ..."
Published: Nov 7th, 2019 3:34 AM
InDEPTH with Brad Byrd: Sudden Recall
"Recently, the drug Natpara was recalled by pharmaceutical company, Takada. It's used to treat hypoparathyroidism. Sandy Keneipp, who lives in ..."
Published: Nov 7th, 2019 2:47 AM
Tmunity Therapeutics' $75 million financing tops recent funding news in Philadelphia
"Philadelphia-based therapeutics and genetics company Tmunity Therapeutics has secured $75 million in Series B funding, according to company ..."
Published: Nov 6th, 2019 10:54 PM
Another Biotech Gets Big Funding
"Westlake Village BioPartners' first investment, a T-Cell therapy startup called Tmunity Therapeutics, raised $75 million in Series B financing, the ..."
Published: Nov 6th, 2019 4:15 PM
Advancing the Treatment of Thyroid Cancer With Targeted Therapies
"Advancing the Treatment of Thyroid Cancer With Targeted Therapies ... or well-differentiated metastatic thyroid cancer, and also for medullary thyroid ..."
Published: Nov 6th, 2019 3:16 PM
Research underway on essential genes in medullary thyroid cancer
""If we were to understand the proteome changes during medullary thyroid cancer tumor development, we thought that perhaps we could target it," ..."
Published: Nov 6th, 2019 1:41 PM
Doctors try CRISPR gene editing for cancer, a 1st in the US
"... by the University of Pennsylvania, the Parker Institute for Cancer Immunotherapy in San Francisco, and a biotech company, Tmunity Therapeutics."
Published: Nov 6th, 2019 1:01 PM
Crispr Takes Its First Steps in Editing Genes to Fight Cancer
"The research was paid for by the Parker Institute for Cancer Immunotherapy and the company Tmunity. Some members of the research team, but not ..."
Published: Nov 6th, 2019 12:30 PM
Biotherapeutics company enters partnership to design future clinical programs
"East Norriton-based Tmunity Therapeutics, a private clinical-stage biotherapeutics company focused on next-generation T-cell immunotherapy, ..."
Published: Nov 5th, 2019 11:00 AM
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery ...
"Planned new drug applications for avapritinib for advanced systemic mastocytosis and pralsetinib for previously treated RET fusion non-small cell lung ..."
Published: Nov 4th, 2019 5:56 PM
Philadelphia life sciences companies team up to advance cancer care
"Two Philadelphia life sciences companies are teaming up to advance cancer care. Tmunity Therapeutics, a developer of next-generation T-cell ..."
"... previous two quarters, thanks to competition facing Shire's legacy hemophilia drugs and a surprise U.S. recall of Natpara. Astellas is paying Pandion ..."
Published: Oct 31st, 2019 10:18 PM
Tmunity Secures $75M in Series B Financing
"Tmunity Therapeutics, a Philadelphia, PA-based T-cell immunotherapy company, closed a $75m Series B financing. The round was led by ..."
Published: Oct 31st, 2019 8:26 PM
Andreessen Horowitz Leads $75 Million Financing for Tmunity Therapeutics
"Tmunity Therapeutics Inc. has raised a $75 million Series B funding led by Andreessen Horowitz to propel a series of cancer-fighting cellular therapies ..."
Published: Oct 31st, 2019 2:48 PM
Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales
"Cometriq (cabozantinib capsules), for the treatment of medullary thyroid cancer, generated $4.4 million in net product revenues. Total collaboration ..."
Published: Oct 31st, 2019 1:30 PM
Tmunity aims to be the next big biotech win for Philly, raising $75 million from Silicon Valley
"Tmunity Therapeutics, a four-year-old firm developing cancer treatments based on University of Pennsylvania T-cell immunotherapy, has raised ..."
Published: Oct 31st, 2019 12:49 PM
Hemophilia rivalry eats away at post-Shire Takeda-and its Natpara recall bites, too
"Before Takeda scored its $59 billion Shire takeover, critics pointed out threats to the Irish drugmaker's bread-and-butter hemophilia franchise."
Published: Oct 31st, 2019 11:03 AM
Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to ...
"Oz Azam beefs up Tmunity's total raise to $231M as they steer toward human data in the drive to cell therapy 2.0. The CEO of Tmunity believes that if ..."
Published: Oct 31st, 2019 10:52 AM
Andreessen Horowitz leads $75M round for Tmunity as it eyes phase 2 studies for 2021
"The new funding will bankroll R&D, clinical development and manufacturing both for the vectors that deliver Tmunity's treatments as well as the cell ..."
Published: Oct 30th, 2019 3:00 PM
Early Detection Impacts Treatment Decisions in Thyroid Cancers
"Either way, the role of early detection of thyroid cancer is of utmost ... such as medullary thyroid cancer (MTC), differentiated thyroid cancer (DTC), and ..."
Published: Oct 29th, 2019 11:00 AM
Interpace to Present Data at the ATA Annual Meeting
"... other providers who focus on the diagnosis and treatment of thyroid cancer. ... "Molecular diagnosis of medullary thyroid carcinoma by NGS mutation ..."
Published: Oct 25th, 2019 10:52 AM
Don't Sleep on These 2 Pharmaceutical Stocks
"The acquisition also brought Eli Lilly LOXO-292, a promising cancer treatment that could launch next year, and LOXO-305, another cancer treatment ..."
"... acute treatment of migraine, a new indication for Taltz, positive data readouts for selpercatinib (LOXO-292) and a negative readout for pegilodecakin ..."
Published: Oct 22nd, 2019 9:56 AM
Eli Lilly Reports Earnings Tomorrow. Here's What to Expect.
"The company has reported some promising data in recent months, including a strong response rate for its drug LOXO-292 in some lung cancer ..."
Published: Oct 21st, 2019 3:33 PM
Bernie urges FDA to swiftly resolve drug recall
"In response to Takeda Pharmaceuticals recalling Natpara, a lifesaving drug used to manage blood calcium levels for people with a rare condition ..."
Published: Oct 21st, 2019 6:22 AM
Vietnamese surgeons succeed in operating on three-year-old with thyroid cancer
"Vietnamese surgeons succeed in operating on three-year-old with thyroid ... on an three-year-old kid with metastasized medullary thyroid cancer."
Published: Oct 18th, 2019 7:18 PM
Bernie Sanders, 2 other lawmakers urge FDA to resolve Natpara shortage
"Takeda recalled Natpara, a treatment for a rare, but potentially fatal calcium-depleting disease, Sept. 5 after it discovered rubber particles in the vials ..."
Published: Oct 18th, 2019 6:02 PM
Leahy, Sanders, Welch Urge FDA to Swiftly Resolve Critical Drug Recall
"Peter Welch (D-Vt.) urged the Food and Drug Administration (FDA) to swiftly resolve the recall of Natpara, a lifesaving drug used to manage blood ..."
"LOXO-292 is a very selective RET inhibitor. Based on recent phase I/II studies, among over 100 patients with advanced-stage, RET fusion-positive ..."
Published: Oct 18th, 2019 11:48 AM
Ipsen adds Blueprint's FOP rare disease drug to pipeline for $535m
"Blueprint also develops cancer drugs. It is developing avapritinib for certain gastrointestinal tumours, and its BLU-667 is in development for cancers ..."
Published: Oct 14th, 2019 4:24 PM
Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance
"... cancer (NSCLC) and RET-mutant medullary thyroid carcinoma (MTC). The company plans to submit an NDA for pralsetinib pertaining to the NSCLC ..."
Published: Oct 14th, 2019 4:09 PM
FDA Awards $4.1 Billion In Funding For Rare Disease Research
"The grants will specifically go to research for medullary thyroid carcinoma and Duchenne muscular dystrophy, but these subsequent findings will likely ..."
Published: Oct 14th, 2019 3:22 PM
NextUp: Tmunity Therapeutics Is Pioneering Personalized Cancer Treatments
"Who: Tmunity Therapeutics was founded in 2015 by a team of experienced researchers, including Bruce Blazar, Bruce Levine, Yangbing Zhao, Jim ..."
Published: Oct 14th, 2019 12:56 PM
Eli Lilly Stock Gets 2 Pieces of Good News
"The company, however, has announced some promising data in recent months, including a 68% response rate for its experimental drug LOXO-292 ..."
Published: Oct 12th, 2019 12:22 AM
A pain in the neck
"Two other kinds of thyroid cancer - medullary and undifferentiated, which are extremely rare in that they make for less than one per cent of all thyroid ..."
Published: Oct 10th, 2019 2:37 PM
Lung Cancer Therapy Makes Major Advances
"At the World Conference on Lung Cancer, we saw results with LOXO-292 in a cohort of approximately 105 patients with RET-positive lung cancer."
Published: Oct 10th, 2019 12:00 PM
Precision oncology: Exciting clinical developments and complicated biology
"Drilon and colleagues presented results from the LIBRETTO clinical study of selpercatinib (LOXO-292, Loxo Oncology) in September at International ..."
Published: Oct 9th, 2019 12:11 AM
Coverage Initiated on US-Based Precision Therapy Developer
"... pointed out that H.C. Wainwright and key opinion leaders view the market opportunities for both avapritinib and pralsetinib to be "underappreciated."
Published: Oct 8th, 2019 3:22 PM
FDA awards two grants for natural history studies in rare diseases
"University of Texas MD Anderson Cancer Center (Houston, Texas), Elizabeth Grubbs, prospective study in medullary thyroid carcinoma, ..."
Published: Oct 7th, 2019 1:18 PM
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292."
Published: Oct 4th, 2019 4:30 PM
At ESMO, more precision medicines show their worth
"... test group, people with RET-mutant medullary thyroid cancer who had previously received Cometriq (cabozantinib) and/or Caprelsa (vandetanib)."
Published: Oct 4th, 2019 3:32 PM
Precision Medicine for RET Fusion-Positive NSCLC
"Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable ..."
Published: Oct 3rd, 2019 2:09 PM
Here's Why You Should Add Thermo Fisher to Your Portfolio
"... identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients, who may be treated with Lilly's investigational therapy, LOXO-292."
Published: Oct 3rd, 2019 11:15 AM
UPDATE: HC Wainwright Starts Blueprint Medicines (BPMC) at Buy
"... suitable for long-term treatment; (3) while LOXO-292 has previously been perceived as the best-in-class RET inhibitor, physician feedback suggests ..."
Published: Oct 3rd, 2019 11:09 AM
UPDATE: HC Wainwright Starts Blueprint Medicines (BPMC) at Buy
"... NDA submissions for avapritinib in advanced systemic mastocytosis (AdvSM) and pralsetinib (BLU-667) in 2L RET-fusion non-small cell lung cancer ..."
Published: Oct 2nd, 2019 6:56 PM
Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 ...
"... mutations occur in approximately 60% of sporadic medullary thyroid cancer, ... As you recall, data in RET fusion positive non-small cell lung cancer ..."
Published: Oct 2nd, 2019 3:56 PM
BioIndiana Hotbed: Home to a Thriving Biopharma Industry
"One of the assets, LOXO-292, hit the mark as a monotherapy for the treatment of RET fusion-positive non-small cell lung cancer in a Phase I/II trial."
Published: Oct 2nd, 2019 10:52 AM
The Alliance for Regenerative Medicine Announces Election of 2020 ARM Officers, Executive ...
"WASHINGTON, D.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international ..."
Published: Oct 2nd, 2019 1:27 AM
Selpercatinib in RET Fusion-Positive Thyroid Cancer
"Selpercatinib (previously known as LOXO-292) is an oral and selective investigational new agent that is being evaluated for the treatment of patients ..."
Published: Oct 1st, 2019 5:37 PM
Penn spinoff licenses experimental cancer immunotherapy from CHOP
"Penn spinoff Tmunity Therapeutics Inc. has entered into an exclusive license and research collaboration agreement with Children's Hospital of ..."
Published: Oct 1st, 2019 10:52 AM
Tmunity Announces Exclusive License and Research Collaboration with Children's Hospital of ...
"Collaboration broadens Tmunity's pipeline of pediatric oncology therapies. - Expansion potential into other hard-to-treat solid tumors."
Published: Sep 30th, 2019 11:48 PM
Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib
"The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292."
Published: Sep 30th, 2019 12:22 PM
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for ...
"... of wildtype and mutated RET kinases as compared to proxy chemical compounds for investigational RET inhibitors, LOXO-292 and BLU-667."
Published: Sep 30th, 2019 10:47 AM
Eli Lilly Says Selpercatinib Shows 'Demonstrative Efficacy and Safety' in RET-Altered Thyroid ...
"In the RET-mutant medullary thyroid cancer population, selpercatinib achieved a 56% overall response rate (ORR) in patients who had prior treatment ..."
Published: Sep 30th, 2019 9:50 AM
Vantage Esmo 2019 roundup
"Thyroid results strengthen selpercatinib's case. 29 September. As selpercatinib confirms its activity in thyroid cancer, Lilly gears up to prove the Ret ..."
Published: Sep 30th, 2019 5:15 AM
Gemma Collins' weight loss jabs - the risks of the hunger fighting injections revealed
"However, it adds: "It is not known if Victoza will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people."."
Published: Sep 29th, 2019 6:56 PM
Selpercatinib Demonstrates Robust ORR in Thyroid Cancer
"Selpercatinib Demonstrates Robust ORR in Thyroid Cancer ... selpercatinib (formally LOXO-292) in patients with RET-mutant medullary thyroid cancer ..."
Published: Sep 29th, 2019 5:36 PM
Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected
"The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates (ORR) for patients with ..."
Published: Sep 29th, 2019 2:26 PM
ESMO: Lilly's RET drug shrinks more than half of rare thyroid cancers
"It's a different conversation with non-medullary thyroid cancers: "They are more molecularly diverse in a way that is helpful to our story. Today, BRAF ..."
Published: Sep 25th, 2019 7:18 PM
Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach
"Eli Lilly announced that it had achieved positive results from a phase 1/2 study using the drug selpercatinib to treat RET fusion-positive non-small cell ..."
Published: Sep 25th, 2019 4:18 PM
What to look out for at ESMO 2019
"At the start of the year, when Eli Lilly (NYSE: LLY) bought Loxo Oncology, the potential of its first-in-class oral RET inhibitor LOXO-292 was central to ..."
Published: Sep 23rd, 2019 11:37 PM
Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And ...
"Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing ..."
Published: Sep 23rd, 2019 7:30 PM
Lilly, Bayer's tumor-agnostic cancer drug gets European nod
"Another company, Blueprint Medicines, has a competing RET inhibitor in development, BLU-667 (pralsetinib). Analysts have remarked that the ..."
Published: Sep 23rd, 2019 10:41 AM
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019
"Selpercatinib is being investigated in RET fusion-positive cancers across tumor types and RET-mutant medullary thyroid cancer (MTC). RET fusions ..."
Published: Sep 22nd, 2019 1:18 PM
Thyroid Cancer Awareness Month
"And, unlike many other cancers, the mortality rate for thyroid cancer has ... Papillary (and variants), Follicular (including Hurthle Cell), Medullary and ..."
Published: Sep 20th, 2019 4:18 PM
Patients Who Use Natpara Say They are Suffering After Recall
"In this segment, we talk to Becky Buckman who took part in the clinical trials for Natpara and says the drug is a lifesaver. She is now part of a group of ..."
Published: Sep 20th, 2019 4:07 PM
Drugs in the Pipeline: Non-Small-Cell Lung Cancer
"Several promising drugs for the treatment of lung cancer have been ... papillary thyroid cancer (PTC), RET-mutant medullary thyroid cancer (MTC), ..."
Published: Sep 20th, 2019 2:48 PM
FDA approves Rybelsus (semaglutide), the first GLP-1 analog treatment available in a pill for ...
"These may be symptoms of thyroid cancer. ... It is not known if Rybelsus will cause thyroid tumors or a type of thyroid cancer called medullary thyroid ..."
Published: Sep 20th, 2019 10:41 AM
CHMP Issues Positive Opinion to Expand Trulicity (dulaglutide) Label to Include Results from ...
"It is not known if Trulicity will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Patients should not ..."
Published: Sep 19th, 2019 9:56 AM
Thyroid Cancer: Knowing The Facts This Thyroid Cancer Awareness Month
"A small gland located at the base of the neck, the thyroid is part of our ... People with a family history of thyroid cancer, especially medullary thyroid ..."
Published: Sep 18th, 2019 6:56 PM
Selpercatinib Promising in RET Fusion-Positive NSCLC
"... platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy; RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, ..."
Published: Sep 18th, 2019 1:41 PM
It's really scary Recall of Natpara leaves patients in limbo"
"Natpara was recalled this month because tiny pieces of rubber from the injector were found in some vials of the drug, which could contaminate the ..."
Published: Sep 18th, 2019 6:23 AM
NorCal patients live in fear after parathyroid drug recall
"People suffering from a rare, but potentially deadly disease are now living in fear after their life-saving medication called Natpara was suddenly ..."
Published: Sep 16th, 2019 7:30 PM
How a Once-Weekly Injection Can Help Manage Type 2 Diabetes
"It is unknown whether BYDUREON BCise causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, as the human ..."